


Iconographie




Dossier 3 – Question 1




Dossier 27 – Question 15




Dossier 7 – Question 2




Dossier 30 – Question 4




Dossier 8 – Question 2




Dossier 27 – Question 4




Dossier 8 – Question 6




Dossier 22 – Énoncé




Dossier 2 – Question 2




Dossier 11 – Question 4




Dossier 10 – Question 2



Dossier 32 – Question 9




Dossier 19 – Question 8



Dossier 31 – Question 9




Dossier 24 – Question 10




Dossier 13 – Question 2



Dossier 4 – Énoncé



Dossier 15 – Question 3




Dossier 25 – Question 3




Dossier 26 – Question 4



Dossier 28 – Question 5




Dossier 11 – Question 13




Dossier 12 – Question 6




Dossier 29 – Question 9




Dossier 10 – Question 6




Dossier 13 – Question 4




Dossier 25 – Question 5




Dossier 14 – Question 5




Dossier 16 – Question 12



Dossier 24 – Question 11



Dossier 17 – Question 9




Dossier 31 – Question 10



Dossier 25 – Question 6



Dossier 22 – Question 7




Dossier 7 – Question 7



Dossier 24 – Question 15



Dossier 23 – Question 3




Dossier 32 – Question 9




Dossier 25 – Question 8




Dossier 26 – Question 10




Dossier 24 – Question 11




Dossier 14 – Question 2




Dossier 12 – Question 7



Dossier 24 – Question 13




Dossier 27 – Question 6



Dossier 25 – Question 3

Date visite	LIN	Théo	LSN	Pré	%Th.	Post 1	%Chi
Heure du test				03.02.16		03.02.16	
Substance				16:03		16:13	
						AIROMIR	
CVF [L]	2.46	3.47	4.47	2.61	75	2.87	10
VEMS [L]	1.90	2.73	3.57	0.86	32	1.06	23
VEMS % CVF [%]	45.61	78.85	112.10	33.06	42	37.01	12
VEMS % CV MAX [%]	64.08	75.87	87.66	32.88	43	37.01	13
DEP [L/s]	5.52	7.51	9.50	2.32	31	2.31	-1
DEM 75 [L/s]	3.84	6.66	9.47	0.66	10	0.85	28
DEM 50 [L/s]	1.74	3.91	6.08	0.37	9	0.47	27
DEM 25 [L/s]		1.30	2.59	0.21	16	0.25	19
DEMM 25/75 [L/s]	1.46	3.17	4.88	0.34	11	0.43	27
VIMS [L]				2.01		2.07	3
DEM 50 % DIM 5Q[%]				18.30		22.96	25
Capacité Vitale [L]	2.67	3.59	4.51	2.60	72	2.87	10
CPT [L]	4.87	6.02	7.18	7.18	119		
VR [L]	1.63	2.30	2.98	4.58	199		
CRFpl [L]	2.33	3.31	4.30	6.05	183		
VRE [L]	1.01	1.01	1.01	1.47	146		
CI [L]	2.58	2.58	2.58	1.12	44		
VR % CPT [%]	29.55	38.53	47.51	63.82	166		

Dossier 24 – Question 13



Dossier 26 – Question 9

Date		Théo	Pré 19/02/16	%Pré/Théo	Post 19/02/16	%Post/Théo
CVF	[L]	4.01	3.00	74.8	3.04	75.7
VEMS	[L]	3.05	2.13	69.8	2.04	66.8
VEMS % CVF	[%]		70.87		66.99	
VEMS % CV MAX	[%]	74.07	64.37	86.9	66.99	90.4
DEMM 25/75	[L/s]	3.01	1.54	51.2	1.44	47.7
DEM 75	[L/s]	7.13	3.51	49.2	2.81	39.4
DEM 50	[L/s]	4.13	2.14	51.8	2.06	49.8
DEM 25	[L/s]	1.41	0.61	43.4	0.76	54.0
DEP	[L/s]	7.94	3.55	44.7	3.24	40.9
VIMS	[L]		1.80		1.92	
DIM 50	[L/s]		1.50		1.52	
CV MAX	[L]	4.16	3.31	79.4	3.04	73.0
VRE	[L]	1.02	0.77	75.0		
CI	[L]	3.14	2.54	80.8		
CRF(Pleth)	[L]	3.73	4.67	125.2		
VR	[L]	2.71	3.90	144.2		
CPT	[L]	7.14	7.21	100.9		
VR % CPT	[%]	42.43	54.16	127.6		

Dossier 24 – Question 5



Dossier 26 – Question 8

I. *Escherichia coli*

Antibiogramme		I
PENICILLINES		
Ampicilline	R	>16
Amoxi+Ac.clavulanique	R	16
Ticarcilline	R	>64
Pipéra+Tazobactam	R	64
CEPHALOSPORINES		
Céfalotine	I	32
Céfoxitine	S	<=4
Céfotaxime	S	<=1
Ceftazidime	S	<=1
CARBAPENEMES		
Imipénème	S	<=0.250
Ertapénème	S	<=0.500
AMINOSIDES		
Gentamicine	S	<=1
Tobramycine	S	<=1
Amikacine	S	<=2
QUINOLONES		
Acide Nalidixique	S	<=2
Ofloxacine	S	<=0.250
Ciprofloxacine	S	<=0.250
SULFAMIDES-TRIMETHOPRIME		
Triméthoprime/sulfaméthox azole	S	

S:sensible I:intermédiaire R:résistant C:CMI en cours


D:sensibilité diminuée B:Bas Niveau de Résistance H:Haut Niveau de Résistance



Dossier 24 – Question 14



Dossier 4 – Question 3



Dossier 4 – Question 13



Dossier 4 – Question 3

Items traités

N° d'item	Titre de l'item	N° de dossier											
		1	2	3	4	5	6	7	8	9	10	11	12
Item 73	Addiction au tabac	x											x
Item 108	Troubles du sommeil de l'adulte					x							
Item 132	Thérapeutiques antalgiques, médicamenteuses et non médicamenteuses								x				
Item 147	Otites infectieuses de l'adulte et de l'enfant												
Item 151	Infections broncho-pulmonaires communautaires de l'adulte		x								x		
Item 154	Septicémie/Bactériémie/Fongémie de l'adulte et de l'enfant										x		
Item 155	Tuberculose												
Item 159	Coqueluche									x			
Item 162	Grippe												
Item 180	Accidents du travail et maladies professionnelles : maladies respiratoires d'origine professionnelle									x			
Item 182	Hypersensibilités et allergies chez l'enfant et l'adulte												
Item 184	Asthme, rhinite												
Item 188	Pathologies auto-immunes												
Item 199	Dyspnée aigüe et chronique										x		
Item 200	Toux chronique de l'adulte												
Item 201	Hémoptysie												
Item 202	Epanchement pleural								x	x			
Item 203	Opacités et masses intrathoraciques chez l'enfant et l'adulte			x									
Item 204	Insuffisance Respiratoire Chronique	x											
Item 205	Bronchopneumopathie Chronique Obstructive	x											
Item 206	Pneumopathies Interstitielles Diffuses							x			x		
Item 207	Sarcoïdose		x										
Item 222	Hypertension artérielle pulmonaire												
Item 224	Embolie pulmonaire et thrombose veineuse profonde						x				x		
Item 228	Orientation diagnostique devant une douleur thoracique aiguë et chronique												
Item 326	Prescription et surveillance des classes médicamenteuses les plus courantes chez l'adulte et chez l'enfant		x			x							
Item 306	Tumeurs du poumon, primaires et secondaires			x						x			
Item 333	Œdème de Quincke et anaphylaxie												
Item 354	Détresse Respiratoire de l'adulte	x						x					
Item 356	Orientation diagnostique et conduite à tenir devant un pneumothorax												
Item 329	Prise en charge immédiate, évaluation des complications précoce chez un traumatisé thoracique								x				

N° de dossier																			
13	14	15	16	17	18	19	20	21	22	23	24	25	26	27	28	29	30	31	32
							X	X										X	
							X												
					X	X	X								X		X		
X		X																	
							X												
								X	X										
								X	X										
										X							X		
										X							X		
											X							X	
											X								X
											X								
												X							
												X							
												X							
													X						
													X						
													X						
														X					
														X					
															X				
																X			
																	X		
																		X	
																			X

